CD8A and glioblastoma: In a NSCLC, melanoma, and glioblastoma cohort, TxflSig exhibited superiority to several effective ICB biomarkers in predicting response to ICB treatments, including TIDE [45], MSI.score (microsatellite instability) [47,48], CD274 (PD-L1) [49], CD8 [50], and INFG (INFγ) [51] (Figure 3B).